No abstract

Hidradenitis suppurativa (HS) is a chronic, systemic, inflammatory dermatosis which lacks curative treatment. Its management can be challenging, thus a variety of therapies are commonly used, such as antibiotics, anti-inflammatory drugs, retinoids, surgery and biological treatments. Adalimumab is the only approved biological therapy for HS, while secukinumab, risankizumab or guselkumab are currently under investigation with ongoing trials for HS. 1,2 To our knowledge, there are currently no clinical trials being conducted to assess the efficacy of ustekinumab in HS. The present study provides some extra evidence about the effectiveness and safety of ustekinumab in HS.

A rare soft tissue tumor masquerading as a parathyroid adenoma in a patient with Birt-Hogg-Dub e syndrome and multiple cervical endocrinopathies.

No abstract

No abstract